Abstract 350P
Background
The diagnosis and treatment of breast cancer involves changes in personal, family, social, professional and sexual relationships. In this study we assessed sexual satisfaction in patients with early breast cancer using the validated SEXSAT-Q scale.
Methods
We used the SEXSAT-Q quality of life questionnaire in 60 patients diagnosed with early breast cancer at our centre. Six dimensions were studied: 1. Loss of sexual desire. 2. Alteration of body image. 3. Psychological coping. 4. Discomfort during sexual intercourse. 5. Satisfaction during sexual intercourse. 6. Satisfaction with breast reconstruction. Data were collected in Medical Oncology Department during March 2023.
Results
A sample of 60 patients was selected, aged 26-72 years old, with a median age of 52 years, who had undergone breast cancer surgery, 73.33% by conservative surgery. 20% were premenopausal, 10% were perimenopausal and 70% were menopausal. 35% were being treated with chemotherapy, 56.67% with hormonoterapy and 8.33% with anti-HER2. 78.33% had a stable partner and did not use contraception. 30% of patients were quite or very sad and depressed since starting treatment. 50% of patients believe that the treatment has worsened their body image. 75% reported that during treatment their sexual relations were not satisfactory. 61.67% believe that their sexual desire has decreased and 45% admit having more problems reaching orgasm since diagnosis.
Conclusions
Women with curable breast cancer it is important to know the impact of diagnosis and treatment on the sexual sphere. The SEXSAT-Q questionnaire is a validated scale capable of measuring the sexual satisfaction of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M.L. Garrido Onecha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Incidence and prognostic value of HER2-low expression metastatic breast cancer in Asian population: A 10-year retrospective study
Presenter: Thanate Dajsakdipon
Session: Poster session 03
435P - Phase II single arm study of durvalumab and olaparib (D+O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)
Presenter: Takeo Fujii
Session: Poster session 03
436P - Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial)
Presenter: Hui Cao
Session: Poster session 03
437P - Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app
Presenter: Bela Mrinakova
Session: Poster session 03
438P - Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 03
439P - Testing HR+ / HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
Presenter: Anastasios Boutis
Session: Poster session 03
440P - Palliative radiotherapy in metastatic breast cancer: Does molecular subtype predict patient response to radiotherapy?
Presenter: Meriem El Bessi
Session: Poster session 03
441P - Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study
Presenter: Achim Woeckel
Session: Poster session 03
442P - Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001)
Presenter: Federico Waisberg
Session: Poster session 03
443P - Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer
Presenter: Cengiz Karacin
Session: Poster session 03